Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

Authors:

Abstract
No abstract available
Funding Information
  • SNF
  • UZH
  • University Hospital Zurich

This publication has 27 references indexed in Scilit: